We are live on ! Find out more
AMYT

Amryt Pharma plc American Depositary Shares
AMYT

Delisted

AMYT was delisted on the 11th of April, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Amryt Pharma plc American Depositary Shares in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 79 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 79 → 0 (-79)

100% less funds holding in top 10

Funds holding in top 10: 11 → 0 (-11)

100% less capital invested

Capital invested by funds: $720M → $0 (-$720M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 79

Holders
–
Holders Change
-79
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-11
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
79
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
ACM
Athyrium Capital Management
New York
-$129M
2
HCM
Highbridge Capital Management
New York
-$92.3M
3
SCM
Stonepine Capital Management
Oregon
-$91.5M
4
MAM
MPM Asset Management
Massachusetts
-$38.9M
5
Morgan Stanley
Morgan Stanley
New York
-$36.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
– -$5.33M -365,383 Closed
Qube Research & Technologies (QRT)
27
Qube Research & Technologies (QRT)
United Kingdom
– -$4.73M -324,303 Closed
CL
28
CSS LLC
Illinois
– -$4.56M -312,886 Closed
SB
29
Samsara BioCapital
California
– -$4.44M -304,715 Closed
Wells Fargo
30
Wells Fargo
California
– -$4.08M -279,495 Closed
SCS
31
Syquant Capital SAS
France
– -$3.76M -258,000 Closed
CM
32
Capula Management
Cayman Islands
– -$3.59M -246,460 Closed
YCM
33
Yakira Capital Management
Connecticut
– -$3.06M -209,917 Closed
FLC
34
Fifth Lane Capital
Texas
– -$2.77M -190,244 Closed
N
35
Natixis
France
– -$2.77M -190,232 Closed
Jane Street
36
Jane Street
New York
– -$2.59M -177,421 Closed
GF
37
Gabelli Funds
New York
– -$2.45M -168,147 Closed
Goldman Sachs
38
Goldman Sachs
New York
– -$2.39M -163,968 Closed
AM
39
Anqa Management
New York
– -$2.29M -156,694 Closed
HM
40
Harvest Management
New York
– -$2.18M -149,500 Closed
EPM
41
Equitec Proprietary Markets
Illinois
– -$1.82M -124,806 Closed
TC
42
Tejara Capital
United Kingdom
– -$1.77M -121,148 Closed
GCIA
43
Gabelli & Co Investment Advisers
New York
– -$1.67M -114,722 Closed
PFMU
44
Privium Fund Management (UK)
United Kingdom
– -$1.51M -103,775 Closed
CCM
45
Cinctive Capital Management
New York
– -$1.46M -100,000 Closed
Renaissance Technologies
46
Renaissance Technologies
New York
– -$1.44M -98,700 Closed
PCM
47
PenderFund Capital Management
British Columbia, Canada
– -$1.88M -95,370 Closed
QOP
48
Quinn Opportunity Partners
Virginia
– -$1.25M -86,000 Closed
CF
49
Cantor Fitzgerald
New York
– -$1.2M -81,966 Closed
AA
50
AlphaCentric Advisors
Puerto Rico
– -$1.18M -81,000 Closed
1
2
3 4

AMYT Hedge Fund Activity: Q2 2023 in Review

0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Amryt Pharma plc American Depositary Shares (AMYT) for Q2 2023, worth a combined $0 — down 100% from $720M a quarter earlier.

Sellers outnumbered buyers: 79 funds closed out of AMYT and 0 opened new positions — a net loss of 79 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Athyrium Capital Management, exiting entirely with an estimated $129M sold.

  • 0 institutional investors held Amryt Pharma plc American Depositary Shares (AMYT) as of Q2 2023, down from 79 in Q1 2023.
  • Funds reported $0 of Amryt Pharma plc American Depositary Shares stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Amryt Pharma plc American Depositary Shares positions in Q2 2023 and 79 closed out, a net change of -79 holders.
  • The largest Amryt Pharma plc American Depositary Shares seller in Q2 2023 was Athyrium Capital Management, an estimated $129M sold.

Based on aggregated 13F filings for Q2 2023.